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Background and PurposeᄏAt least 100 Ryanodine receptor type 1 (RYR1) mutations asso-
ciated with malignant hyperthermia (MH) and central core disease (CCD) have been identified, 
but 2 RYR1 mutations accompanying multiminicore myopathy in an MH and/or CCD family 
have been reported only rarely. 
MethodsᄏFifty-three members of a large MH family were investigated with clinical, histopa-
thologic, RYR1 mutation, and haplotyping studies. Blood creatine kinase (CK) and myoglobin 
levels were also measured where possible. 
ResultsᄏSequencing of the entire RYR1 coding region identified a double RYR1 mutation 
(R2435H and A4295V) in MH/CCD regions 2 and 3. Haplotyping analysis revealed that the 
two missense heterozygous mutations (c.7304G>A and c.12891C>T) were always present on a 
common haplotype allele, and were closely cosegregated with histological multiminicores and 
elevated serum CK. All the subjects with the double mutation showed elevated serum CK and 
myoglobin, and the obtained muscle biopsy samples showed multiminicore lesions, but only 
two family members presented a late-onset, slowly progressive myopathy. 
ConclusionsᄏWe found multiminicore myopathy with clinical and histological variability in 
a large MH family with an unusual double RYR1 mutation, including a typical CCD-causing 
known mutant. These results suggest that multiminicore lesions are associated with the presence 
of more than two mutations in the RYR1 gene. J Clin Neurol 2008;4:123-130
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Malignant hyperthermia (MH) is a genetically heterogene-
ous pharmacogenetic disorder of skeletal muscle that predis-
poses susceptible individuals to a high risk of life-threatening 
hypermetabolic episodes during anesthesia. It is triggered by 
commonly used inhaled anesthetics and/or depolarizing mus-
cle relaxants, which lead to a rapid and sustained increase in 
myoplasmic Ca2+ from the sarcoplasmic reticulum in skeletal 
muscle. This induces skeletal-muscle rigidity, metabolic aci-
dosis, cardiac arrhythmia, and high-fever reactions and, if not 
treated promptly, a possible fatal outcome.1,2 
Central core disease (CCD) is a rare congenital myopathy 
with nonprogressive presentation that is closely associated 
with MH susceptibility (MHS). The diagnosis is mainly based 
on histological characteristics of cores, which are devoid of 
oxidative enzyme activity and predominantly observed in 
type I fibers. Typical clinical features include hypotonia, pro-
nounced proximal muscle weakness, and skeletal anomalies 
such as congenital hip displacement and scoliosis. However, 
there are recent reports of a broader clinical and histological 
spectrum of CCD even within the same family, suggesting that 
using pathology alone can result in an incorrect diagnosis.3-5 
Despite possessing six genetic loci and allelic heterogeneity 
implicated in MH,6,7 the ryanodine receptor type 1 (RYR1) 
gene is a primary locus for MHS [Online Mendelian Inherit-
ance in Man (OMIM) 145600] and CCD (OMIM 117000).8-10 
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160 kb of genomic DNA, maps to chromosome 19q13.1, and 
encodes a protein of 5,038 amino acids. The length and com-
plexity of the RYR1 gene makes comprehensive screening 
for detecting mutation in the RYR1 gene difficult and labo-
rious.11-13 Most of the detected mutations linked to MH and 
CCD are concentrated in three defined regions of the RYR1 
gene: between amino acids 35 and 614 (MH/CCD region 1), 
2,129 and 2,458 (MH/CCD region 2) and 4,214 and 4,914 
(MH/ CCD region 3);14 these have formed the main foci of 
mutation screening. 
Recent analyses of mutations of the entire RYR1 coding 
region have increased the rate of mutation detection and in-
volved searching many novel sequence variants outside the 
three mutational hot spots,15,16 with most being reported as 
point missense mutations. 
Here we report for the first time the presence of an unusual 
double RYR1 mutation (Arg2435His and Ala4295Val) in a 
large Korean MH family with multiminicore myopathy. The 
results illustrate the cosegregation of the two compound mu-
tations with multiminicore myopathy and suggest that signi-
ficant clinical and histological phenotypic variability is asso-




Index patients and clinical examinations 
As shown in Fig. 1, 53 members of the family were includ-
ed in this study. All blood and tissue samples were obtained 
from the 53 consenting family members with ethical approv-
al from the ethics committee of Chonbuk National Hospital. 
Serum creatine kinase (CK) and myoglobin levels were mea-
sured in 24 subjects and muscle biopsies were performed in 
9 subjects (Table 1). 
The investigation of the family started after the MH attack 
of proband III-17. He underwent general anesthesia with thio-
pental sodium, succinylcholine and enflurane for orthopedic 
surgery. About 30 min after anesthesia, he developed hyper-
thermia (40℃), tachycardia (180 beats/min) and generalized 
muscle rigidity, accompanied by dark-colored blood in the 
surgical field and cola-colored urine. His serum myoglobin 
Fig. 1. Pedigree and haplotyping analysis of the present family. Arrows denote probands who experienced malignant hyperthermia episodes
or individuals showing overt clinical myopathies. Black shapes indicate individuals with histological multiminicore lesions. Empty shapes and
a question mark denote individuals in whom muscle biopsies and genetic tests were not performed, respectively. Genotypes: +/-, heterozy-
gous carrier of R2435H and A4295V mutations; -/-, no mutation. The results of marker typing and identification of the mutation are shown
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and CK levels were >500 ng/mL and 25,000 IU/L, respecti-
vely. He was treated with dantrolene sodium (2 mg/kg) and 
recovered without any sequelae. According to the clinical 
grading scale,17 the MH raw score was calculated as 78, and 
this episode could be classified as Group 6, almost certainly 
corresponding to MH. Individual III-4 died when she was 20 
years old due to an MH attack during the correction of con-
genital ptosis under succinylcholine and halothane.18 Indivi-
dual III-9, a 9-year-old female, developed an MH attack du-
ring general anesthesia for appendectomy, but was treated 
with dantrolene sodium and recovered completely. 
Only two of the family members, individuals II-1 and III-
7, showed clinically evident myopathy. They were father and 
son, and presented late-onset chronic progressive muscle 
weakness and atrophy of the hip girdle and the proximal por-
tion of the lower legs. A thorough history-taking from the 
father revealed that mild muscle weakness of the lower limbs 
first appeared at the age of 30 years, with the subsequent slow 
progression of muscle wasting. Finally, at 65 years of age, he 
showed marked muscle atrophy that meant that he could not 
stand or walk without a support (MRC grade IV-). The son 
was 27 years old when a physical examination was performed 
by a neurologist (Sunwoo IN) and he complained of muscle 
weakness of the lower limbs since he was 24 years old. Mus-
cle weakness and wasting of the lower limbs subsequently 
gradually progressed over 10 years, and he found it very 
difficult to stand or to climb stairs. 
 
Ryanodine receptor type 1 mutation analysis 
Genomic DNA was extracted from whole blood samples 
using the GENErALLTM nucleic acid purification kit (General 
Biosystem, Korea) according to the manufacturer’s instruc-
tions. Mutation analyses for two MH probands (III-9 and 
III-17) and two myopathic patients (II-1 and III-7) were per-
formed from the entire coding region of the RYR1 gene by 
a polymerase chain reaction (PCR) concatenation and se-
quencing method, as described previously.19 Briefly, all PCR 
primer pairs for amplification were designed in the appro-
priate regions of intron sequences from genomic DNA (all 
of the primer sequences are available on request). Comple-
mentary 5’ tails for 12-bp overlapping concatenation arms 
were added to the primers to form concatemers. The second 
round of PCR for the concatenation reaction was performed 
using the first-round PCR product as the template. The con-
Table 1. Laboratory and genetic findings of the family members
Individual CK (IU/L) Myoglobin (ng/mL) Muscle biopsy Mutation (R2435H/A4295V) Age (years)/Sex 
I-9 993 319 NT +/+ 76/M 
II-1 312 244 Multiminicores +/+ 70/M 
II-2 54 36 NT -/- 67/F 
II-3 367 57 NT +/+ 43/M 
II-5 259 137 NT +/+ 66/F 
II-9 457 231 Multiminicores +/+ 41/F 
II-11 432 197 Multiminicores +/+ 39/F 
II-13 4,114 1,220 Multiminicores +/+ 38/M 
II-15 832 217 Multiminicores +/+ 59/F 
II-17 573 205 Multiminicores +/+ 56/M 
II-22 121 52 NT -/- 55/M 
II-27 255 132 NT +/+ 45/F 
III-1 1,365 126 Multiminicores +/+ 46/F 
III-3 173 14 NT -/- 43/F 
III-5 195 18 NT -/- 39/F 
III-7 1,840 248 Multiminicores +/+ 34/M 
III-8 205 27 NT +/+ 11/F 
III-9 396 711 NT +/+ 09/F 
III-13 1,031 312 NT +/+ 35/M 
III-15 563 93 NT +/+ 33/F 
III-17* 25,075 1,375 Multiminicores +/+ 22/M 
III-29 265 54 NT +/+ 30/F 
III-38 185 72 NT -/- 18/M 
III-39 83 23 NT -/- 15/F 
*Individual III-17 as a proband showed laboratory findings during an MH episode. +/+ or -/-: presence or absence of both R2435H and 







Double RYR1 Mutation in a MH Family 
 126 J Clin Neurol 2008;4:123-130
catenated PCR products were purified using the QIAquick 
PCR purification kit (QIAGEN, USA) for sequencing. The 
purified concatemers were sequenced in both directions using 
BigDye Terminator chemistry on an automatic DNA sequen-
cer (Model 3700, ABI PRISM, USA). The sizes of the first 
PCR products and each concatemer for sequencing ranged 
from 500 to 700 bp. The total number of PCR concatemers 
for bidirectional sequencing was 47, comprising 16 first-round 
PCR products for direct sequencing, and 26 and 5 concate-
mers consisting of 2 and 3 first-round PCR products, res-
pectively. 
 
Mutation screening of the identified R2435H and 
A4295V 
HgaI restriction enzyme analysis was performed for screen-
ing the R2435H mutation, as described previously.20 For 
screening the A4295V mutation using direct sequencing, a 
598-bp product in exon 91 of RYR1 was amplified by PCR 
using forward (5’-tgtagctgccactgcgctgtcg-3’) and reverse (5’-
tgccaggagctcggtcac-3’) primers in a 50-μL reaction mixture 
with 200-500 ng of gDNA, each primer at 0.2 μM, each 
dNTP at 2.5 mM, 2 mM MgCl2, 50 mM KCl and 2.5 U of 
TAKARA LA TaqTM with GC buffer (TAKARA BIO, Japan). 
The reaction consisted of an initial 1-min denaturation at 94℃, 
followed by 30 cycles of 94℃ for 30 sec, 60℃ for 30 sec and 
72℃ for 2 min. The PCR product was purified and directly 
sequenced in both directions. The two mutations were also 
screened in samples from 100 normal controls. 
 
Haplotyping analysis 
The D19S191, D19S422, D19S220, D19S190 and D19S223 
chromosome-19 microsatellite markers flanking the RYR1 
locus from members of the family, as described previously,21 
were genotyped using a DNA analyzer (ABI 3100) in con-
junction with GENESCAN and GENOTYPER software (Ap-
plied Biosystems, Foster City, CA). 
 
Histological studies 
Muscle specimens were obtained from the vastus lateralis 
or biceps brachii under local anesthesia in nine individuals 
harboring the R2435H and A4295V mutations. Specimens 
were frozen immediately in isopentane-cooled liquid nitrogen 
and stored at -80℃ until processed for histochemistry studies. 
Sections of fresh-frozen muscle were stained for hematoxylin 
and eosin, adenosine triphosphatase (ATPase), periodic acid-
Schiff, Sudan Black and nicotinamide adenine dinucleotide 
dehydrogenase-tetrazolium reductase (NADH-TR). Speci-
mens for electron microscopy were fixed in 5% glutaralde-
hyde and 1% osmium tetraoxide in 0.1 M cacodylate buffer. 
Histochemistry and electron microscopy samples were pro-




The presented pedigree contained two probands (III-9 and 
III-17) who survived MH episodes, one individual (III-4) 
who died from an MH episode, and two patients (II-1 and 
III-7) showing clinically definite myopathy. 
 
Ryanodine receptor type 1 mutation analysis 
A double mutation (Arg2435His and Ala4295Val) was si-
multaneously identified in the family from scanning mutations 
of the entire RYR1 coding region. A known c.7304G>A mu-
tation in exon 45 was responsible for the substitution of an 
arginine by a histidine residue at position 2,435 of RYR1 



























Exon 45 Exon 91
Fig. 2. DNA sequencing of the regions 
of the ryanodine receptor type 1 (RYR1)
gene in which the 7304CGC>CAC (Arg
2435His) missense mutation in exon 45 
and 12891GCG>GTG (Ala4295Val) mis-
sense mutation in exon 91 were detec-
ted. Individual III-3 without the two mu-
tations showed a single peak, but in-
dividual III-17 (a proband with an MH
episode) showed two superimposed 
peaks (arrows) in both exons 45 and 91,
indicating heterozygous missense muta-
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the substitution of a conserved alanine by a valine residue at 
position 4295 (A4295V). These two mutations were missense 
and heterozygous (Fig. 1). Twenty-eight family members with 
the R2435H mutation (Fig. 2) were diagnosed as having MHS 
without performing the invasive in vitro contracture test ac-
cording to guidelines of the European Malignant Hyperther-
mia Group (EMHG).23  
Neither of the two mutations were detected in the 100 
normal controls. Additionally, 20 silent polymorphisms with 
heterozygous or homozygous changes were identified throug-
hout the RYR1 gene, 7 of which were identified for the first 
time, as presented in Table 2. 
 
Mutation screening of R2435H and A4295V, and 
haplotyping analysis 
The two R2435H and A4295V mutations were screened 
by HgaI enzyme digestion20 and a direct sequencing method, 
respectively. Twenty-eight of the 53 family members were 
compound heterozygous individuals harboring the two RYR1 
mutations (Fig. 2, Table 1). Haplotyping analysis showed that 
both mutations were always present in the 4-6-8-3-7 common 
haplotype for the D19S191, D19S220, D19S422, D19S190 
and D19S223 markers, and cosegregated with multiminicore 
lesions in muscle specimens, and showed variably elevated 
serum CK and myoglobin (Fig. 2, Table 1). 
 
Histochemistry and electron microscopy findings 
Histochemistry revealed variation in fiber size with increas-
ing internal nuclei, and multiminicore structures with scat-
tered moth-eaten appearances and unclear border margins. 
There was no type I fiber predominance, which is known to 
be one of pathognomonic findings of CCD (Fig. 3). The elec-
tron microscopy examination of the samples revealed similar 
minicore-like structures with a mean cross-sectional diameter 




The present study is the first showing a double RYR1 mu-
tation (Arg2435His and Ala4295Val) in a MH family with 
features of multiminicore myopathy, which differs from typi-
cal CCD with the R2435H mutation only. Members of this 
family with the double mutation showed elevated serum CK 
and myoglobin, and the obtained muscle biopsy samples 
showed multiminicore lesions, but only two members repre-
sented a late-onset, slowly progressive myopathy. 
Table 2. Mutations and polymorphisms identified from the entire RYR1 coding regions in the family
Nucleotide change* Mutation Protein alteration Gene location Reference† 
Mutations     
c.7304G>A Heterozygous p.Arg2435His Exon 45 PMID8220422 
c.12891C>T Heterozygous p.Ala4295Val Exon 91 This study 
Polymorphisms     
c.594G>A Heterozygous p.Leu198Leu Exon 7 U48452 
c.1077T>C Homozygous p.Ala359Ala Exon 11 J05200 
c.1116G>A Heterozygous p.Lys372Lys Exon 11 This study 
c.1669G>A Homozygous p.Ser557Ser Exon 15 J05200 
c.2223C>T Heterozygous p.Asp741Asp Exon 19 This study 
c.2286T>C Homozygous p.Pro762Pro Exon 19 AC011469 
c.2943A>G Homozygous p.Thr981Thr Exon 24 AC011469 
c.2979C>T Homozygous p.Asn993Asn Exon 24 This study 
c.3456C>T Heterozygous p.Ile1152Ile Exon 26 This study 
c.7089C>T Heterozygous p.Cys2363Cys Exon 44 This study 
c.7098C>T Heterozygous p.Pro2366Pro Exon 44 This study 
c.7209C>T Heterozygous p.Arg2403Arg Exon 44 This study 
c.7500G>A Heterozygous p.Ala2500Ala Exon 47 AB209425 
c.7527G>A Heterozygous p.Val2509Val Exon 47 AB209425 
c.7977G>A Heterozygous p.Thr2659Thr Exon 50 AB209425 
c.8118T>C Heterozygous p.Ile2706Ile Exon 51 AB209425 
c.8190T>C Heterozygous p.Asp2730Asp Exon 51 AB209425 
c.9186A>G Heterozygous p.Pro3062Pro Exon 62 AB209425 
c.9690G>A Heterozygous p.Leu3230Leu Exon 66 AB209425 
c.10218C>T Heterozygous p.Tyr3406Tyr Exon 67 AB209425 
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Most RYR1 mutations associated with MH and CCD have 
been reported as a private mutation having a single missense 
mutation in a family.14,24 However, the family in the present 
study showed two amino acid substitutions in the 4-6-8-3-7 
common haplotype of the RYR1 gene (Fig. 1), which was 
completely inherited as an autosomal dominant trait over 
three generations (Fig. 2). Therefore, this family differs from 
a few reported MH cases having two RYR1 mutants located 
on each haplotype arising from their affected parent.21,25,26 
Only one previously report described the presence of two 
RYR1 mutants (R2676W and T2787S) in the same copy of 
the RYR1 gene in an MHS family.27 
In addition to the R2435H mutation, which was reported 
previously20,28 and included in the list of 22 (EMHG) and 17 
(North American Malignant Hyperthermia Group) RYR1 
mutations for MHS and CCD,23,29 the combined A4295V sub-
stitution might play an important role in the variable myo-
pathic phenotypes. However, it was difficult to assess the 
pathogenic role of A4295V substitution in this family due to 
the uniform presence of the two mutations on the same allele. 
There are several reasons for considering the A4295V sub-
stitution a candidate mutation for MHS and/or multiminicore 
myopathy: 1) it segregated with the multiminicore lesions 
and elevated blood CK and myoglobin; 2) it was located in 
the mutational hot spot of MH/CCD region 3 and relatively 
close to the V4234L mutation, which is known to cause 
MHS;30 3) the alanine at amino acid position 4,295 is conser-
ved in vertebrates (Fig. 5); 4) it was not found in the family 
members without the common haplotype or in the 100 unre-
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Fig. 3. Muscle biopsy sections stained 
for NADH-TR with a scattered moth-
eaten appearance and unstained mul-
timinicores in the father (II-1, A) and
subtle moth-eaten changes in his son
(III-7, B). 
A B 
Fig. 4. Electron micrographs showing 
streaming and disruption of irregular Z-
lines, and the amorphous cores from in-
dividuals III-17 (A) and III-1 (B). 
Fig. 5. Amino acid sequence alignments
in the region of RYR1 isoforms flanking 
the A4295V mutation in human, pig and 
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tion occurred in a CpG dinucleotide, which is consistent with 
the observation that most mutations of the RYR1 gene (but 
not polymorphisms) occur in CpG dinucleotide sequences, 
presumably through fixing of T：G mismatch premutations 
arising from deamination of 5-methyl-cytidine residues.31,32 
However, the extent to which the A4295V substitution contri-
butes to the pathogenic effects requires further investigation. 
A study showing a high occurrence of multiminicore le-
sions in the MHS family found two mutations of R2676W 
and T2787S throughout the RYR1 cDNA.27 Because the T27- 
87S substitution was identified in another MHS family, those 
authors suggested that the second R2676W substitution is 
responsible for the cores. Also, there are a few reports of se-
gregation between the presence of two RYR1 mutations and 
the cores or multiminicores in one family.33,34 In the same 
way, the presence of the A4295V mutation in addition to the 
known R2435H mutation might have been responsible for 
the multiminicore lesions in the present family. Also, our 
results suggest that the multiminicore or core lesions are as-
sociated with more than two RYR1 mutations. 
Clinical and histopathological overlap among different con-
genital myopathies could be responsible for the diagnostic 
dilemma. Therefore, identifying the genetic determinants 
might aid a definitive diagnosis.34 The identification of the 
known R2435H mutation in the present family strongly sug-
gested that CCD was present. The typical symptoms of CCD 
comprise congenital hypotonia, nonprogressive proximal mus-
cle weakness, and myopathic facies.35 However, the clinical 
features in the present family were quite different and more 
variable. Among the 28 family members with the 2 muta-
tions (Fig. 2), 2 subjects (II-1 and III-7) showed an overt cli-
nical myopathy with a late-onset and slow progression, while 
there were no clinical myopathic symptoms among the other 
family members despite the presence of elevated serum CK 
and myoglobin. On the contrary, some individuals (particu-
larly I-9 and II-13) had a burly physique despite having both 
multiminicore lesions and markedly elevated serum CK and 
myoglobin. In addition to the variable phenotypes from the 
same mutations, the muscle specimens also showed inconsi-
stent findings. The son (III-7) showed no obvious core struc-
tures with the oxidative enzyme stain, whereas his father (II-
1) exhibited numerous multiminicores. This finding is con-
sistent with the core structures being a secondary phenomenon 
that appears with aging or disease progression.4,36 Overall, 
the clinical and histological features in the present family 
raise the possibility of a chronic progressive myopathy with 
multiminicores in which clinical severity is not correlated 
well with the pathologic findings and the levels of blood CK 
and myoglobin. 
To date, the complexity of the RYR1 gene has meant that 
the detection of mutations therein has focused on three muta-
tional hot spots. Recent mutation analysis of the entire RYR1 
coding region by the DHPLC method and sequencing of 
full-length leukocyte RYR1 cDNA has increased the rate of 
detection of mutations in up to 70% of affected MH fami-
lies.15,37 In the present study, we used PCR concatenation 
followed by sequencing, which reduced the PCR fragments 
for sequencing from 106 to 47 per patient. We consider that 
this could be a clinically useful genetic test for scanning 
mutations of the entire RYR1 coding region, considering that 
sequencing is a final confirmatory step for DNA-based dia-
gnosis. Additionally, 20 silent polymorphisms including 7 
novel ones were detected in the RYR1 coding region. There-
fore, scanning of the entire RYR1 coding region should be 
carefully considered, especially in cases with variable or un-
usual clinical and pathologic phenotypes. 
In conclusion, we found a double RYR1 mutation (Arg- 
2435His and Ala4295Val) in a MH family with multimini-
core myopathy. The two amino acid substitutions were found 
in the common haplotype of the RYR1 gene with an auto-
somal dominant trait. In addition to the Arg2435His mutation, 
which has previously been shown to cause CCD, the novel 
Ala4295Val substitution is a candidate mutation responsible 
for multiminicore myopathy. 
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